IE
INDV icon

Israel Englander’s Indivior Pharmaceuticals INDV Stock Holding History

Israel Englander’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.1M Sell
2,098,945
-2,496,590
-54% -$90.6M 0.03% 585
2026
Q1 		$140M Buy
4,595,535
+2,257,850
+97% +$74.6M 0.06% 322
2025
Q4 		$83.9M Buy
2,337,685
+27,463
+1% +$839K 0.04% 504
2025
Q3 		$55.7M Sell
2,310,222
-1,086,691
-32% -$22.7M 0.02% 787
2025
Q2 		$50.1M Buy
3,396,913
+931,199
+38% +$10.8M 0.02% 817
2025
Q1 		$23.5M Buy
2,465,714
+1,232,708
+100% +$13M 0.01% 1368
2024
Q4 		$15.3M Buy
1,233,006
+332,180
+37% +$3.42M 0.01% 1746
2024
Q3 		$8.78M Buy
900,826
+407,513
+83% +$4.77M ﹤0.01% 2302
2024
Q2 		$7.95M Buy
493,313
+160,282
+48% +$2.89M ﹤0.01% 2302
2024
Q1 		$7.13M Buy
+333,031
New +$6.26M ﹤0.01% 2506

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's INDV Position: Q2 2026 in Review

Israel Englander reduced its Indivior Pharmaceuticals (INDV) stake by 54% in Q2 2026, selling an estimated $90.6M and leaving 2,098,945 shares worth $86.1M. The position accounts for 0.03% of the portfolio, ranked #585.

Israel Englander first reported a position in INDV in Q1 2024 and has held it in 10 quarters since. The position peaked at $140M in Q1 2026. 335 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Israel Englander held 2,098,945 shares of Indivior Pharmaceuticals worth $86.1M as of Q2 2026.
  • Israel Englander sold 2,496,590 Indivior Pharmaceuticals shares in Q2 2026, an estimated $90.6M.
  • Indivior Pharmaceuticals made up 0.03% of Israel Englander's portfolio in Q2 2026, its #585 holding.
  • Israel Englander first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Israel Englander's Indivior Pharmaceuticals position peaked at $140M in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.